Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates

Core Insights - Azitra, Inc. reported significant progress in its clinical programs during Q3 2025, including the initiation of a Phase 1/2 trial for ATR-04 targeting EGFRi-associated rash in oncology patients [3][6] - The company presented positive preclinical data for ATR-01, aimed at treating ichthyosis vulgaris, a genetic disorder affecting approximately 1.3 million people in the U.S. [3][6] - Azitra's lead program, ATR-12, targets Netherton syndrome, a rare skin disease with no approved treatments, and is in a Phase 1b clinical trial [3][5] Business Highlights - The first patient was dosed in the Phase 1/2 trial for ATR-04 in August 2025, which has received Fast Track designation from the FDA [3][6][8] - Positive preclinical data for ATR-01 was presented at BIO-Europe, showcasing the potential for active filaggrin delivery [3][6] - The company raised $2.8 million in gross proceeds through an equity line of credit with Alumni Capital LP [6] Financial Results - R&D expenses for Q3 2025 were $1.2 million, up from $1.0 million in Q3 2024 [7] - G&A expenses decreased to $1.6 million in Q3 2025 from $1.9 million in Q3 2024 [7] - The net loss for Q3 2025 was $2.8 million, compared to a net loss of $1.0 million in the same period of 2024 [7][12] Cash Position - As of September 30, 2025, Azitra had cash and cash equivalents of $1.4 million, down from $4.6 million at the end of 2024 [7][12]